Abbott Laboratories ABT
Set alert
At close · Oct 30
After hours · Oct 30, 7:21 PM ET
- YTD
- -15.24%
- 1 year
- -14.82%
- Open
- 106.15
- Prev close
- 104.57
- Mkt cap
- 184.98B
- Vol
- 8.44M
- Avg vol
- 8.76M
- EPS
- 2.69
- P/E
- 39.48
- Div yield
- 2.41%
More statistics
- Low
- 104.60
- High
- 106.85
- Forward P/E
- 17.89
- Beta
- 0.58
- Short ratio
- 1.84
- Inst. own
- 81.90%
- Dividend
- 2.52
- Ex-div date
- Oct 14, 2026
- Earnings
- Jan 28, 2027
- 50-d avg
- 104.50
- 200-d avg
- 101.79
- 1y target
- 118.52
5D chart
Events in this range
- Oct 27, 2026Downgrade: Argus Research · Buy → Hold
Signals (115)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 3:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 3:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 2:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:20 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:15 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:30 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:05 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:30 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:25 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:50 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:40 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:30 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:05 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:00 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:40 AM | 3 days ago |
| SMA: Bearish | Oct 29, 11:35 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:35 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 11:10 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 11:05 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:55 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:35 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:20 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:05 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bearish | Oct 28, 3:55 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bullish | Oct 28, 3:20 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:50 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 2:00 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:50 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:50 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:05 PM | 4 days ago |
| SMA: Bearish | Oct 28, 11:35 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:30 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bearish | Oct 28, 10:25 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:00 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:50 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:40 PM | 5 days ago |
| RSI: Oversold | Oct 27, 3:30 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:35 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| RSI: Overbought | Oct 27, 1:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:00 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 10:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 26, 3:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:55 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:25 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 11:35 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:20 AM | 6 days ago |
| SMA: Bullish | Oct 26, 10:55 AM | 6 days ago |
| SMA: Bearish | Oct 26, 10:50 AM | 6 days ago |
News
5 hours ago prnewswire.com
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System
SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary…
3 days ago fool.com
2 Stocks That Could Quietly Become Big Winners in the Artificial Intelligence (AI) Revolution
These aren't top AI stocks, but the technology is helping improve their businesses.
-
3 days ago benzinga.com
Abbott Initiates CROWN-MV Pivotal Trial Evaluating Safety And Effectiveness Of Its Investigational Cephea Mitral Valve System For Symptomatic Mitral Valve Disease
CROWN-MV pivotal trial evaluating the safety and effectiveness of its investigational Cephea™ Mitral Valve System in treating people with symptomatic mitral valve disease who are not candidates for…
3 days ago prnewswire.com
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease
CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for…
3 days ago seekingalpha.com
Best Dividend Aristocrats For November 2026
Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's…
4 days ago finbold.com
U.S. politician makes super suspicious Big Tech stock trades
Republican Rep. Pete Sessions of Texas has disclosed substantial stock sales involving major technology companies.
5 days ago 247wallst.com
Medtronic Has Raised Its Dividend for 49 Years. These 2 Rivals Have Even Longer Streaks
Medtronic's 49-year dividend streak sounds impressive until you meet the two medical device rivals that have been raising payouts even longer, and the differences in yield, valuation, and balance…
5 days ago zacks.com
Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm…
5 days ago zacks.com
Is Most-Watched Stock Abbott Laboratories (ABT) Worth Betting on Now?
Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
5 days ago seekingalpha.com
Abbott: Demand Headwinds And Litigation Risks Priced-In - Spin-Off Tailwinds Ahead
FQ4'26 noise from EP/CGM demand headwinds has contributed to Abbott's lowered FY2026 guidance and range-bound stock price action afterwards. Nutrition spin-off may unlock…
5 days ago benzinga.com
This M&T Bank Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded M&T Bank, Bank of Hawaii, HubSpot, Abbott and Moderna; Bank of Hawaii cut its target, while HubSpot’s rose.
5 days ago defenseworld.net
Abbott Laboratories $ABT Shares Purchased by Evergreen Capital Management LLC
Evergreen Capital Management LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 40.4% during the third quarter, according to the company in its most recent disclosure with the…
6 days ago fool.com
This Dividend King Just Announced Great News for Investors
Abbott Laboratories' third-quarter results were somewhat mixed, with the company's nutrition business still dragging down sales growth. The healthcare leader announced that it would spin off its…
-
6 days ago benzinga.com
Abbott Announces Commercial Availability Of Oncodetect Molecular Residual Disease Test
Abbott (NYSE: ABT) today announced the commercial availability of its next-generation Oncodetect® MRD test, a personalized, tumor-informed, whole-genome sequencing test designed to provide molecular…
6 days ago prnewswire.com
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment
Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of…
6 days ago seekingalpha.com
Abbott Laboratories: A New Growth Story Takes Shape
Abbott Laboratories remains a Buy, driven by robust device and diagnostics growth and the strategic spin-off of its Nutrition business. Devices and diagnostics now comprise 70% of revenue, with…
6 days ago seekingalpha.com
Best Dividend Kings: October 2026
Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized…
1 week ago fool.com
Abbott Laboratories vs. UnitedHealth: Does Health Innovation or Health Insurance Make for a Better Stock to Buy?
Abbott Laboratories maintains a highly diversified healthcare business spanning medical technology, diagnostics, and nutrition. UnitedHealth Group dominates the insurance and healthcare services…
1 week ago seekingalpha.com
The Dividend Aristocrats Ranked By Quality Scores (October 2026)
I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data…
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $120
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $119 to $120.
-
1 week ago benzinga.com
Abbott's New Beta-CORRECT Data At ESMO Congress Demonstrates 30% Enhancement In Sensitivity For Colorectal Cancer Recurrence Within Two Years Of Surgery
Abbott (NYSE:ABT) today announced new Beta-CORRECT data presented at the European Society for Medical Oncology (ESMO) Congress showing that the whole-genome sequencing (WGS)-based Oncodetect®…
1 week ago prnewswire.com
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer
Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer…
1 week ago defenseworld.net
Abbott Laboratories $ABT Shares Sold by Axxcess Wealth Management LLC
Axxcess Wealth Management LLC lessened its stake in Abbott Laboratories (NYSE: ABT) by 67.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange…
-
1 week ago benzinga.com
Citigroup Maintains Buy on Abbott Laboratories, Lowers Price Target to $122
Citigroup analyst Joanne Wuensch maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $125 to $122.
-
1 week ago benzinga.com
RBC Capital Maintains Outperform on Abbott Laboratories, Lowers Price Target to $125
RBC Capital analyst Kendall Au maintains Abbott Laboratories (NYSE:ABT) with a Outperform and lowers the price target from $130 to $125.
-
1 week ago benzinga.com
Wells Fargo Maintains Overweight on Abbott Laboratories, Raises Price Target to $119
Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and raises the price target from $112 to $119.
1 week ago zacks.com
Abbott's Q3 Earnings Call Focuses on Nutrition Spin-Off and Outlook
Abbott plans to spin off its $8.5B Nutrition business by 2027 while cutting its 2026 sales growth outlook amid diabetes pricing and electrophysiology challenges.
1 week ago marketbeat.com
Cologuard Is Working—So Why Isn't Abbott Stock?
Abbott Laboratories NYSE: ABT delivered its third-quarter earnings report on Oct. 21. The stock dropped about 4% in early trading, as the results were merely solid, at a time when investors wanted…
-
1 week ago benzinga.com
JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118
JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.
-
1 week ago benzinga.com
TD Cowen Maintains Buy on Abbott Laboratories, Lowers Price Target to $118
TD Cowen analyst Joshua Jennings maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $118.
-
1 week ago benzinga.com
Baird Maintains Outperform on Abbott Laboratories, Raises Price Target to $123
Baird analyst David Rescott maintains Abbott Laboratories (NYSE:ABT) with a Outperform and raises the price target from $121 to $123.
-
1 week ago benzinga.com
BTIG Maintains Buy on Abbott Laboratories, Lowers Price Target to $125
BTIG analyst Marie Thibault maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $134 to $125.
1 week ago fool.com
Abbott: 3 Key Takeaways for Long-Term Investors
Abbott announced a tax-free spin-off of its nutrition business. Third-quarter comparable sales grew 7% year over year.
1 week ago benzinga.com
SpaceX Jumps 10%, Nasdaq 100 Rises as AI Trade Returns: Stock Market Today
SpaceX's blowout third quarter and Super Micro's guidance hike revive the AI trade, lifting the Nasdaq 100 as Netflix and AT&T slide on results.
1 week ago benzinga.com
Abbott CEO Rules Out Selling $8.5 Billion Nutrition Business: 'No Interest'
Abbott (ABT) to spin off its $8.5B nutrition arm, makers of Ensure & Similac, by end of 2027. Stock dips following Q3 results.
1 week ago benzinga.com
Meta, Tesla On Deck Wednesday As AI Spending, Auto Demand Face Test
Meta Platforms and Tesla headline Wednesday’s reports, with investors focused on whether AI investment can keep driving growth while Tesla’s core auto business weakens. Philip Morris International,…
1 week ago benzinga.com
Abbott Laboratories Q3 2026 Earnings Call Transcript
Abbott Laboratories (NYSE:ABT) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought…
-
1 week ago benzinga.com
Abbott Laboratories Narrows FY2026 Adj EPS Guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 Est
Abbott Laboratories (NYSE:ABT) narrows FY2026 Adj EPS guidance from $5.45-$5.60 to $5.50-$5.55 vs $5.52 analyst estimate..
-
1 week ago benzinga.com
Abbott Laboratories Q3 Adj. EPS $1.42, Inline, Sales $13.013B Beat $12.998B Estimate
Abbott Laboratories (NYSE:ABT) reported quarterly earnings of $1.42 per share which met the analyst consensus estimate. This is a 9.23 percent increase over earnings of $1.30 per share from the same…
-
1 week ago benzinga.com
Abbott To Spin Off Nutrition Business Into Independent Public Company With $8.5B In Annual Sales; Separation Expected To Be Completed By 2027 End
Separation will unlock potential of both companies to pursue distinct growth and value-creation strategiesThe new Nutrition company will be a global leader in the rapidly growing healthy nutrition…
1 week ago benzinga.com
How To Earn $500 A Month From Abbott Stock Ahead Of Q3 Earnings
Abbott expects Q3 EPS of $1.41 and $12.99B revenue. Its 2.42% dividend requires about $247,767 invested to generate $500 monthly.
1 week ago benzinga.com
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q3 Earnings
Abbott reports Q3 earnings Oct. 21; analysts expect $1.41 EPS and $12.99B revenue. FDA approved CardioMEMS updates.
-
2 weeks ago benzinga.com
TD Cowen Reiterates Buy on Abbott Laboratories, Maintains $135 Price Target
TD Cowen analyst Joshua Jennings reiterates Abbott Laboratories (NYSE:ABT) with a Buy and maintains $135 price target.
3 weeks ago benzinga.com
This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Analysts initiated coverage: Overweight GNRC ($303), Buy ENTG ($200) and VYLR ($87), Neutral SPOT ($540).
-
3 weeks ago benzinga.com
Eli Lilly To Rally Over 21%? Here Are 10 Top Analyst Forecasts For Thursday
Analysts raised targets for Everpure, Eli Lilly and Delek US, while cutting targets for Constellation, Tyler, ArriVent and Netflix.
3 weeks ago benzinga.com
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Neutral on Honeywell Aerospace; Outperform on M&T Bank and SailPoint; Buy on Ambiq Micro; Overweight on Abbott.
3 weeks ago benzinga.com
Micron To Rally Around 187%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P
-
3 weeks ago benzinga.com
Barclays Initiates Coverage On Abbott Laboratories with Overweight Rating, Announces Price Target of $120
Barclays analyst Matt Miksic initiates coverage on Abbott Laboratories (NYSE:ABT) with a Overweight rating and announces Price Target of $120.
3 weeks ago benzinga.com
General Motors To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts raised targets for PTC, Cloudflare, PENN, Microsoft and others, while downgrading PTC and upgrading PENN and Abbott.
-
3 weeks ago benzinga.com
FDA Approves Abbott's Updated CardioMEMS HF System
Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) approval for updates to the CardioMEMS HF System that enable new patient-facing capabilities…